RSV-VM1PB-100μg / 询价
RSV-VM1PB-500μg / 询价
RSV-VM1PB-500μgx2 / 询价
- 客服电话
- 技术支持
HRSV (B, strain 18537) Post-fusion glycoprotein F0 Protein
Recombinant HRSV (B, strain 18537) Post-fusion glycoprotein F0 Protein is expressed from HEK293 with His tag at the C-terminus
The protein has a predicted MW of 55.96 kDa. The protein migrates to 18-25 kDa and 42-50 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
HRSV (B, strain 18537) Post-fusion glycoprotein F0 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized HRSV (B, strain 18537) Post-fusion glycoprotein F0, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-Fusion glycoprotein F0 (101F) Antibody, hFc Tag with the EC50 of 3.4ng/ml and not bind Anti-Fusion glycoprotein F0 (D25) Antibody determined by ELISA.
Respiratory syncytial virus (RSV) is a highly contagious childhood pathogen of the respiratory tract and is divided into two antigenic subtypes, A and B, based on the reactivity of the F and G surface proteins to monoclonal antibodies. Surface protein F (fusion protein) is responsible for fusion of viral and host cell membranes, as well as syncytium formation between viral particles. Its sequence is highly conserved between strains. F protein exists in multiple conformational forms. In the prefusion state (PreF), the protein exists in a trimeric form and contains the major antigenic site Ø which serves as a primary target of neutralizing antibodies in the body.
Post-fusion glycoprotein F0;
[1] Griffiths C, Drews SJ, Marchant DJ. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev. 2017 Jan;30(1):277-319.
[2] Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJM, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JPM. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015 Sep 3;6:8143.
[3] McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013 Nov 1;342(6158):592-8.
